BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35460149)

  • 1. A regression framework for a probabilistic measure of cost-effectiveness.
    Illenberger N; Mitra N; Spieker AJ
    Health Econ; 2022 Jul; 31(7):1438-1451. PubMed ID: 35460149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation.
    Spieker AJ; Illenberger N; Roy JA; Mitra N
    Stat Methods Med Res; 2021 May; 30(5):1306-1319. PubMed ID: 33826460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Net-benefit regression with censored cost-effectiveness data from randomized or observational studies.
    Chen S; Hoch JS
    Stat Med; 2022 Sep; 41(20):3958-3974. PubMed ID: 35665527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nested g-computation: A causal approach to analysis of censored medical costs in the presence of time-varying treatment.
    Spieker AJ; Ko EM; Roy JA; Mitra N
    J R Stat Soc Ser C Appl Stat; 2020 Nov; 69(5):1189-1208. PubMed ID: 34108743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan.
    Shih YC; Pan IW; Tsai YW
    Pharmacoeconomics; 2009; 27(11):947-61. PubMed ID: 19888794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.
    Czoski-Murray C; Lloyd Jones M; McCabe C; Claxton K; Oluboyede Y; Roberts J; Nicholl JP; Rees A; Reilly CS; Young D; Fleming T
    Health Technol Assess; 2012 Dec; 16(50):i-xvi, 1-159. PubMed ID: 23302507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laparoscopic supracervical hysterectomy compared with second-generation endometrial ablation for heavy menstrual bleeding: the HEALTH RCT.
    Cooper K; Breeman S; Scott NW; Scotland G; Hernández R; Clark TJ; Hawe J; Hawthorn R; Phillips K; Wileman S; McCormack K; Norrie J; Bhattacharya S
    Health Technol Assess; 2019 Sep; 23(53):1-108. PubMed ID: 31577219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unicompartmental compared with total knee replacement for patients with multimorbidities: a cohort study using propensity score stratification and inverse probability weighting.
    Prats-Uribe A; Kolovos S; Berencsi K; Carr A; Judge A; Silman A; Arden N; Petersen I; Douglas IJ; Wilkinson JM; Murray D; Valderas JM; Beard DJ; Lamb SE; Ali MS; Pinedo-Villanueva R; Strauss VY; Prieto-Alhambra D
    Health Technol Assess; 2021 Nov; 25(66):1-126. PubMed ID: 34812138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma.
    Stahl JM; Damast S; Bledsoe TJ; An Y; Verma V; Yu JB; Young MR; Lester-Coll NH
    Brachytherapy; 2018; 17(2):399-406. PubMed ID: 29275078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
    Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
    Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
    Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
    Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying the net-benefit framework for analyzing and presenting cost-effectiveness analysis of a maternal and newborn health intervention.
    Hounton S; Newlands D
    PLoS One; 2012; 7(7):e40995. PubMed ID: 22829906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A probabilistic approach for economic evaluation of occupational health and safety interventions: a case study of silica exposure reduction interventions in the construction sector.
    Mofidi A; Tompa E; Mortazavi SB; Esfahanipour A; Demers PA
    BMC Public Health; 2020 Feb; 20(1):210. PubMed ID: 32046683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using inverse-weighting in cost-effectiveness analysis with censored data.
    Willan AR; Lin DY; Cook RJ; Chen EB
    Stat Methods Med Res; 2002 Dec; 11(6):539-51. PubMed ID: 12516988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propensity score and doubly robust methods for estimating the effect of treatment on censored cost.
    Li J; Handorf E; Bekelman J; Mitra N
    Stat Med; 2016 May; 35(12):1985-99. PubMed ID: 26678242
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.